A5101769066- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Pharmacology and Obesity Treatment
- Diabetic Foot Ulcer Assessment and Management
- Neuroendocrine Tumor Research Advances
- Bone health and treatments
- Pressure Ulcer Prevention and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Bone Metabolism and Diseases
- Wound Healing and Treatments
- Vitamin D Research Studies
- Diabetes and associated disorders
- Pregnancy and preeclampsia studies
- TGF-β signaling in diseases
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Peptidase Inhibition and Analysis
- Liver Diseases and Immunity
- Bone health and osteoporosis research
- Pancreatic function and diabetes
- Pancreatic and Hepatic Oncology Research
- Bone and Dental Protein Studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Trace Elements in Health
First Affiliated Hospital of Soochow University
2012-2025
Soochow University
2012-2025
<h3>Importance</h3> Delayed healing of diabetic foot ulcers (DFUs) is known to be caused by dysregulated M1/M2-type macrophages, and restoring the balance between these macrophage types plays a critical role in healing. However, drugs used regulate M1/M2 macrophages have not yet been studied large randomized clinical trials. <h3>Objective</h3> To compare topical application ON101 cream with use an absorbent dressing (Hydrofiber; ConvaTec Ltd) when treating DFUs. <h3>Design, Setting,...
OBJECTIVE We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, once-weekly glucagon-like peptide 1 glucagon receptor dual agonist, in Chinese patients with type diabetes. RESEARCH DESIGN AND METHODS Adults diabetes inadequately controlled diet exercise alone or stable metformin (glycated hemoglobin A1c [HbA1c] 7.0–10.5% [53–91 mmol/mol]) were randomly assigned receive 3 mg mazdutide (n = 51), 4.5 49), 6 1.5 open-label...
Aims . To study the proliferation of osteoblasts and genes expression under normal glucose, high metformin (Met). Methods MG63 osteoblast-like cells were cultured in osteogenic medium supplemented with glucose (glucose 5.5 mmol/L) or 16.7 + (Met 300 μ mol/L mmol/L). Proliferation was detected CCK-8 assay at days 1, 3, 7. Real-time PCR Western blot performed to compare collagen I (Col I), osteocalcin (OCN), osteoprotegerin (OPG), receptor activator for NF- κ B ligand (RANKL), metal matrix...
Aims and Objectives: This study aimed to explore the relationship between HERC6- associated immune response Non-Alcoholic Fatty Liver Disease (NAFLD) screen drug candidates for novel treatments. Materials Methods: Mendelian Randomization (MR) was performed test a genetically predicted increase in HERC6 expression development of NAFLD. A single-cell RNA-seq profile liver tissue with histological characteristics (GSE168933) obtained. The cell type highest score identified, scores across...
To investigate the impact of baseline characteristics on efficacy once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from SUSTAIN China trial.
Background . To study the effectiveness of exenatide with metformin and sequential treatment glargine added to their influence on insulin sensitivity adipose distribution. Methods 20 newly diagnosed obese type 2 diabetic patients were enrolled, 2-month washout metformin, 6-month treatment, administrated sequentially accompanied previous metformin. Glucolipid metabolic parameters compared among groups. Adipose distribution was quantified computerized tomography according anatomy, dividing...
Aims To compare the efficacy and safety of saxagliptin glimepiride in type 2 diabetes (T2D) patients who are inadequately controlled with metformin monotherapy. Materials methods In this 48‐week, multi‐centre, open‐label, randomized, parallel trial (NCT02280486, clinicaltrials.gov ), a total 388 T2D were randomized 1:1 to or groups. The primary endpoint was achievement HbA1c <7.0%, without hypoglycaemia, defined as blood glucose <3.9 mmol/L weight gain <3.0% after 48 weeks...
Treatment with basal insulin in Chinese populations is currently sub-optimal, delayed initiation of treatment and inadequate dose titration. Increasing the initial may be a practicable effective solution to problem A higher will helpful for patients achieve blood glucose target improve satisfaction compliance as well require fewer steps titrate. Considering that overweight obese usually doses because resistance, feasible type 2 diabetes. However, safety an important issue needing considered...
Hard-to-heal diabetic foot ulcers (DFUs) are associated with higher mortality rates and an increased medical burden for patients. ON101, a new topical cream, exhibited better healing efficacy than the control dressing in Phase III trial. In this
Introduction & Objective: Ecnoglutide (XW003) is a cAMP signaling biased GLP-1 analog being developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The primary objective this study was to evaluate efficacy ecnoglutide administered 24 weeks in adults with T2DM. Methods: We conducted Phase 3 randomized, double-blind, placebo-controlled ecnoglutide, enrolling 211 T2DM at 33 sites China. Participants were randomized receive 0.6 or 1.2 mg placebo as once weekly injections...
To evaluate the efficacy and safety of empagliflozin in combination with insulin ± oral antidiabetic drugs (OADs) over 24 weeks, Chinese patients type 2 diabetes (T2D) who had insufficient glycaemic control.This was a randomized, double-blind, placebo-controlled, parallel group, multicentre phase III study. Adult T2D control received up to two OADs were randomized (1:1:1) receive 10 or 25 mg, placebo for weeks. The primary endpoint change from baseline HbA1c at week 24.Of 219 patients, 73...
GLP-1 is an incretin hormone with broad pharmacological potential. receptor agonists (GLP-1RAs) are successfully in clinical use for T2D and obesity. Several GLP-1-based therapies evaluation treating metabolic diseases. Supaglutide (supa), a novel GLP-1RA, late-stage development T2D. The efficacy safety of supa being investigated 297 patients newly diagnosed inadequately controlled diet exercise this randomized, double-blind, placebo-controlled phase 3 trial (NCT04994288). Supa treatment...
<p dir="ltr">OBJECTIVE We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, once-weekly GLP-1 glucagon receptor dual agonist, in Chinese patients with type diabetes. RESEARCH DESIGN AND METHODS Adults diabetes inadequately controlled diet exercise alone or stable metformin (glycated haemoglobin A1c [HbA1c] 7.0%–10.5% [53–91 mmol/mol]) were randomized receive mazdutide 3 mg (n = 51), 4.5 49), 6 open-label dulaglutide...
<p dir="ltr">OBJECTIVE We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, once-weekly GLP-1 glucagon receptor dual agonist, in Chinese patients with type diabetes. RESEARCH DESIGN AND METHODS Adults diabetes inadequately controlled diet exercise alone or stable metformin (glycated haemoglobin A1c [HbA1c] 7.0%–10.5% [53–91 mmol/mol]) were randomized receive mazdutide 3 mg (n = 51), 4.5 49), 6 open-label dulaglutide...
The proliferation of MG63 cells under high glucose intervened with metformin was measured by CCK-8 assay.The activity intracellular alkaline phosphatase (ALP) detected SFBC expression related genes RT-PCR.Metformin promoted the (P＜0.01),the ALP increased (P＜0.05).The expressions collagen Ⅰ and osteocalcin were up-regulated while matrix metalloproteinase (MMP)-1,MMP-2,MMP-3,and MMP-8 down-regulated results indicate that may protect osteoblast,via promoting osteoblast...